From Wikipedia the free encyclopedia
|Disease||Coronavirus disease 2019 (COVID-19)|
|Virus strain||Severe acute respiratory syndrome|
coronavirus 2 (SARS‑CoV‑2)
|Source||Bats, likely indirectly|
|Index case||Wuhan, China|
|Date||17 November 2019 – present|
(2 years and 7 months)
|6,328,974 (reported) |
15–25 million (estimated)
|Part of a series on the|
The COVID-19 pandemic, also known as the coronavirus pandemic, is a global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified from an outbreak in Wuhan, China, in December 2019. Attempts to contain it there failed, allowing the virus to spread worldwide. The World Health Organization (WHO) declared a Public Health Emergency of International Concern on 30 January 2020 and a pandemic on 11 March 2020. As of 25 June 2022, the pandemic had caused more than 543 million cases and 6.32 million confirmed deaths, making it one of the deadliest in history.
COVID-19 symptoms range from undetectable to deadly, but most commonly include fever, dry cough, and fatigue. Severe illness is more likely in elderly patients and those with certain underlying medical conditions. COVID‑19 transmits when people breathe in air contaminated by droplets and small airborne particles containing the virus. The risk of breathing these in is highest when people are in close proximity, but they can be inhaled over longer distances, particularly indoors. Transmission can also occur if contaminated fluids reach the eyes, nose or mouth, and, rarely, via contaminated surfaces. Infected persons are typically contagious for 10 days, and can spread the virus even if they do not develop symptoms. Mutations have produced many strains (variants) with varying degrees of infectivity and virulence.
COVID-19 vaccines have been approved and widely distributed in various countries since December 2020. Other recommended preventive measures include social distancing, wearing masks, improving ventilation and air filtration, and quarantining those who have been exposed or are symptomatic. Treatments include monoclonal antibodies, novel antiviral drugs, and symptom control. Governmental interventions include travel restrictions, lockdowns, business restrictions and closures, workplace hazard controls, quarantines, testing systems, and tracing contacts of the infected.
The pandemic triggered severe social and economic disruption around the world, including the largest global recession since the Great Depression. Widespread supply shortages, including food shortages, were caused by supply chain disruption. The resultant near-global lockdowns saw an unprecedented pollution decrease. Educational institutions and public areas were partially or fully closed in many jurisdictions, and many events were cancelled or postponed. Misinformation circulated through social media and mass media, and political tensions intensified. The pandemic raised issues of racial and geographic discrimination, health equity, and the balance between public health imperatives and individual rights.
The pandemic is known by several names. It is often referred to in news media as the "coronavirus pandemic" despite the existence of other human coronaviruses that have caused epidemics and outbreaks (e.g. SARS).
During the initial outbreak in Wuhan, the virus and disease were commonly referred to as "coronavirus", "Wuhan coronavirus", "the coronavirus outbreak" and the "Wuhan coronavirus outbreak", with the disease sometimes called "Wuhan pneumonia". In January 2020, the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma. WHO finalized the official names COVID-19 and SARS-CoV-2 on 11 February 2020. Tedros Adhanom explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
WHO names variants of concern and variants of interest using Greek letters. The initial practice of naming them according to where the variants were identified (e.g. Delta began as the "Indian variant") is no longer common. A more systematic naming scheme reflects the variant's PANGO lineage (e.g., Omicron's lineage is B.1.1.529) and is used for other variants.
|For country-level data, see:|
As of 25 June 2022
SARS-CoV-2 is a newly discovered virus that is closely related to bat coronaviruses, pangolin coronaviruses, and SARS-CoV. The first known outbreak started in Wuhan, Hubei, China, in November 2019. Many early cases were linked to people who had visited the Huanan Seafood Wholesale Market there, but it is possible that human-to-human transmission began earlier.
The scientific consensus is that the virus is most likely of zoonotic origin, from bats or another closely-related mammal. Despite this, the subject has generated extensive speculation about alternative origins. The origin controversy heightened geopolitical divisions, notably between the United States and China.
The earliest known infected person fell ill on 1 December 2019. That individual did not have a connection with the later wet market cluster. However, an earlier case may have occurred on 17 November. Two-thirds of the initial case cluster were linked with the market. Molecular clock analysis suggests that the index case is likely to have been infected between mid-October and mid-November 2019.
Official "case" counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols whether or not they experienced symptomatic disease. Due to the effect of sampling bias, studies which obtain a more accurate number by extrapolating from a random sample have consistently found that total infections considerably exceed the reported case counts. Many countries, early on, had official policies to not test those with only mild symptoms. The strongest risk factors for severe illness are obesity, complications of diabetes, anxiety disorders, and the total number of conditions.
In early 2020, a meta-analysis of self-reported cases in China by age indicated that a relatively low proportion of cases occurred in individuals under 20. It was not clear whether this was because young people were less likely to be infected, or less likely to develop symptoms and be tested. A retrospective cohort study in China found that children and adults were just as likely to be infected.
Among more thorough studies, preliminary results from 9 April 2020 found that in Gangelt, the centre of a major infection cluster in Germany, 15 per cent of a population sample tested positive for antibodies. Screening for COVID-19 in pregnant women in New York City, and blood donors in the Netherlands, found rates of positive antibody tests that indicated more infections than reported. Seroprevalence-based estimates are conservative as some studies show that persons with mild symptoms do not have detectable antibodies.
Initial estimates of the basic reproduction number (R0) for COVID-19 in January were between 1.4 and 2.5, but a subsequent analysis claimed that it may be about 5.7 (with a 95 per cent confidence interval of 3.8 to 8.9).
In December 2021, the number of cases continued to climb due to several factors, including new COVID-19 variants. As of that 28 December, 282,790,822 individuals worldwide had been confirmed as infected. As of 14 April 2022[update], over 500 million cases were confirmed globally. Most cases are unconfirmed, with the Institute for Health Metrics and Evaluation estimating the true number of cases as of early 2022 to be in the billions.
Total COVID-19 cases per 100,000 people from selected countries
Active COVID-19 cases per 100,000 people from selected countries
As of 25 June 2022, more than 6.32 million deaths had been attributed to COVID-19. The first confirmed death was in Wuhan on 9 January 2020. These numbers vary by region and over time, influenced by testing volume, healthcare system quality, treatment options, government response, time since the initial outbreak, and population characteristics, such as age, sex, and overall health.
Multiple measures are used to quantify mortality. Official death counts typically include people who died after testing positive. Such counts exclude deaths without a test. Conversely, deaths of people who died from underlying conditions following a positive test may be included. Countries such as Belgium include deaths from suspected cases, including those without a test, thereby increasing counts.
Official death counts have been claimed to underreport the actual death toll, because excess mortality (the number of deaths in a period compared to a long-term average) data show an increase in deaths that is not explained by COVID-19 deaths alone. Using such data, estimates of the true number of deaths from COVID-19 worldwide have included a range from 9.5 to 18.6 million by The Economist, as well as over 10.3 million by the Institute for Health Metrics and Evaluation and ~18.2 million (earlier) deaths between 1 January 2020, and 31 December 2021 by a comprehensive international study. Such deaths include deaths due to healthcare capacity constraints and priorities, as well as reluctance to seek care (to avoid possible infection). Further research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic. In May 2022, the WHO estimated the number of excess deaths to be 14.9 million compared to 5.4 million reported COVID-19 deaths, with the majority of the unreported 9.5 million deaths believed to be direct deaths due the virus, rather than indirect deaths. Some deaths were because people with other conditions could not access medical services.
The time between symptom onset and death ranges from 6 to 41 days, typically about 14 days. Mortality rates increase as a function of age. People at the greatest mortality risk are the elderly and those with underlying conditions.
COVID-19 deaths per 100 000 population from selected countries
In May 2022 the World Health Organization estimated that COVID has caused just under 15 million excess deaths worldwide. The virus directly caused most of these deaths but some were because people with other conditions could not access medical services.
Infection fatality ratio (IFR)
The infection fatality ratio (IFR) is the cumulative number of deaths attributed to the disease divided by the cumulative number of infected individuals (including asymptomatic and undiagnosed infections and excluding vaccinated infected individuals). It is expressed in percentage points (not as a decimal). Other studies refer to this metric as the 'infection fatality risk'.
In November 2020, a review article in Nature reported estimates of population-weighted IFRs for various countries, excluding deaths in elderly care facilities, and found a median range of 0.24% to 1.49%.
IFRs rise as a function of age (from 0.002% at age 10 and 0.01% at age 25, to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85). These rates vary by a factor of ~10,000 across the age groups. For comparison, the IFR for middle-aged adults is two orders of magnitude more likely than the annualised risk of a fatal automobile accident and far more dangerous than seasonal influenza.
In December 2020, a systematic review and meta-analysis estimated that population-weighted IFR was 0.5% to 1% in some countries (France, Netherlands, New Zealand, and Portugal), 1% to 2% in other countries (Australia, England, Lithuania, and Spain), and about 2.5% in Italy. This study reported that most of the differences reflected corresponding differences in the population's age structure and the age-specific pattern of infections.
Case fatality ratio (CFR)
Another metric in assessing death rate is the case fatality ratio (CFR),[a] which is the ratio of deaths to diagnoses. This metric can be misleading because of the delay between symptom onset and death and because testing focuses on symptomatic individuals.
Based on Johns Hopkins University statistics, the global CFR is 1.16 percent (6,328,974 deaths for 543,542,602 cases) as of 25 June 2022. The number varies by region and has generally declined over time.
Signs and symptoms
Symptoms of COVID-19 are variable, ranging from mild symptoms to severe illness. Common symptoms include headache, loss of smell and taste, nasal congestion and runny nose, cough, muscle pain, sore throat, fever, diarrhoea, and breathing difficulties. People with the same infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhoea. In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of cases.
The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles (that form an aerosol) that infected people exhale as they breathe, talk, cough, sneeze, or sing. Infected people are more likely to transmit COVID-19 when they are physically close. However, infection can occur over longer distances, particularly indoors.
SARS‑CoV‑2 belongs to the broad family of viruses known as coronaviruses. It is a positive-sense single-stranded RNA (+ssRNA) virus, with a single linear RNA segment. Coronaviruses infect humans, other mammals, including livestock and companion animals, and avian species. Human coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome (MERS, fatality rate ~34%). SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV.
The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests, which detects the presence of viral RNA fragments. As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited." The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. The WHO has published several testing protocols for the disease.
Preventive measures to reduce the chances of infection include getting vaccinated, staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, managing potential exposure durations, washing hands with soap and water often and for at least twenty seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.
Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.
A COVID‑19 vaccine is intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the severity and death caused by COVID‑19.
For the first two years of the pandemic, no specific and effective treatment or cure was available. In 2021, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) approved the oral antiviral protease inhibitor, Paxlovid (nirmatrelvir plus AIDS drug ritonavir), to treat adult patients. FDA later gave it an EUA.
Most cases of COVID-19 are mild. In these, supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms (fever, body aches, cough), adequate intake of oral fluids and rest. Good personal hygiene and a healthy diet are also recommended.
Supportive care includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning, and medications or devices to support other affected vital organs. More severe cases may need treatment in hospital. In those with low oxygen levels, use of the glucocorticoid dexamethasone is recommended, to reduce mortality. Noninvasive ventilation and, ultimately, admission to an intensive care unit for mechanical ventilation may be required to support breathing. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure.
Existing drugs such as hydroxychloroquine, lopinavir/ritonavir, ivermectin and so-called early treatment are not recommended by US or European health authorities. Two monoclonal antibody-based therapies are available for early use in high-risk cases. The antiviral remdesivir is available in the US, Canada, Australia, and several other countries, with varying restrictions; however, it is not recommended for use with mechanical ventilation, and is discouraged altogether by the World Health Organization (WHO), due to limited evidence of its efficacy.
Several variants have been named by WHO and labelled as a variant of concern (VoC) or a variant of interest (VoI). They share the more infectious D614G mutation: Delta dominated and then eliminated earlier VoC from most jurisdictions. Omicron's immune escape ability may allow it to spread via breakthrough infections, which in turn may allow it to coexist with Delta, which more often infects the unvaccinated.
The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalization. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to intensive care units (ICU).
Many countries attempted to slow or stop the spread of COVID-19 by recommending, mandating or prohibiting behaviour changes, while others relied primarily on providing information. Measures ranged from public advisories to stringent lockdowns. Outbreak control strategies are divided into elimination and mitigation. Experts differentiate between elimination strategies (commonly known as "zero-COVID") that aim to completely stop the spread of the virus within the community, and mitigation strategies (commonly known as "flattening the curve") that attempt to lessen the effects of the virus on society, but which still tolerate some level of transmission within the community. These initial strategies can be pursued sequentially or simultaneously during the acquired immunity phase through natural and vaccine-induced immunity.
Containment is undertaken to stop an outbreak from spreading into the general population. Infected individuals are isolated while they are infectious. The people they have interacted with are contacted and isolated for long enough to ensure that they are either not infected or no longer contagious. Screening is the starting point for containment. Screening is done by checking for symptoms to identify infected individuals, who can then be isolated or offered treatment. The Zero-COVID strategy involves using public health measures such as contact tracing, mass testing, border quarantine, lockdowns and mitigation software to stop community transmission of COVID-19 as soon as it is detected, with the goal of getting the area back to zero detected infections and resuming normal economic and social activities. Successful containment or suppression reduces Rt to less than 1.
Should containment fail, efforts focus on mitigation: measures taken to slow the spread and limit its effects on the healthcare system and society. Successful mitigation delays and decreases the epidemic peak, known as "flattening the epidemic curve". This decreases the risk of overwhelming health services and provides more time for developing vaccines and treatments.
Individual behaviour changed in many jurisdictions. Many people worked from home instead of at their traditional workplaces.
Non-pharmaceutical interventions that may reduce spread include personal actions such as hand hygiene, wearing face masks, and self-quarantine; community measures aimed at reducing interpersonal contacts such as closing workplaces and schools and cancelling large gatherings; community engagement to encourage acceptance and participation in such interventions; as well as environmental measures such as surface cleaning. Many such measures were criticised as hygiene theatre.
More drastic actions, such as quarantining entire populations and strict travel bans have been attempted in various jurisdictions. China and Australia's lockdowns have been the most strict. New Zealand implemented the most severe travel restrictions. South Korea introduced mass screening and localised quarantines, and issued alerts on the movements of infected individuals. Singapore provided financial support, quarantined, and imposed large fines for those who broke quarantine.
Contact tracing attempts to identify recent contacts of newly infected individuals, and to screen them for infection; the traditional approach is to request a list of contacts from infectees, and then telephone or visit the contacts.
Another approach is to collect location data from mobile devices to identify those who have come in significant contact with infectees, which prompted privacy concerns. On 10 April 2020, Google and Apple announced an initiative for privacy-preserving contact tracing. In Europe and in the US, Palantir Technologies initially provided COVID-19 tracking services.
WHO described increasing capacity and adapting healthcare as a fundamental mitigation. The ECDC and WHO's European regional office issued guidelines for hospitals and primary healthcare services for shifting resources at multiple levels, including focusing laboratory services towards testing, cancelling elective procedures, separating and isolating patients, and increasing intensive care capabilities by training personnel and increasing ventilators and beds. The pandemic drove widespread adoption of telehealth.
Due to capacity supply chains limitations, some manufacturers began 3D printing material such as nasal swabs and ventilator parts. In one example, an Italian startup received legal threats due to alleged patent infringement after reverse-engineering and printing one hundred requested ventilator valves overnight. On 23 April 2020, NASA reported building, in 37 days, a ventilator which is undergoing further testing. Individuals and groups of makers created and shared open source designs, and manufacturing devices using locally sourced materials, sewing, and 3D printing. Millions of face shields, protective gowns, and masks were made. Other ad hoc medical supplies included shoe covers, surgical caps, powered air-purifying respirators, and hand sanitizer. Novel devices were created such as ear savers, non-invasive ventilation helmets, and ventilator splitters.
In July 2021, several experts expressed concern that achieving herd immunity may not be possible because Delta can transmit among vaccinated individuals. CDC published data showing that vaccinated people could transmit Delta, something officials believed was less likely with other variants. Consequently, WHO and CDC encouraged vaccinated people to continue with non-pharmaceutical interventions such as masking, social distancing, and quarantining if exposed.
In February 2022, the Icelandic Ministry of Health lifted all restrictions and adopted a herd immunity approach, and in June 2022 the Icelandic Ministry of Health's chief epidemiologist Þórólfur Guðnason said that "we have acquired a good herd immunity, because otherwise the situation would be much worse."
Living with COVID-19
The outbreak was discovered in Wuhan in November 2019. It is possible that human-to-human transmission was happening before the discovery. Based on a retrospective analysis starting from December 2019, the number of cases in Hubei gradually increased, reaching 60 by 20 December and at least 266 by 31 December.
A pneumonia cluster was observed on 26 December and treated by Doctor Zhang Jixian. She informed the Wuhan Jianghan CDC on 27 December. Vision Medicals reported the discovery of a novel coronavirus to the China CDC (CCDC) on 28 December.
On 30 December, a test report from CapitalBio Medlab addressed to Wuhan Central Hospital reported an erroneous positive result for SARS, causing doctors there to alert authorities. Eight of those doctors, including Li Wenliang (who was also punished on 3 January), were later admonished by the police for spreading false rumours; and Ai Fen was reprimanded. That evening, Wuhan Municipal Health Commission (WMHC) issued a notice about "the treatment of pneumonia of unknown cause". The next day, WMHC made the announcement public, confirming 27 cases—enough to trigger an investigation.
Official Chinese sources claimed that the early cases were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. However, in May 2020, CCDC director George Gao indicated the market was not the origin (animal samples had tested negative).
On 11 January, WHO was notified by the Chinese National Health Commission that the outbreak was associated with exposures in the market, and that China had identified a new type of coronavirus, which it isolated on 7 January.
Initially, the number of cases doubled approximately every seven and a half days. In early and mid-January, the virus spread to other Chinese provinces, helped by the Chinese New Year migration. Wuhan was a transport hub and major rail interchange. On 10 January, the virus's genome was shared through GISAID. A retrospective study published in March found that 6,174 people had reported symptoms by 20 January. A 24 January report indicated human transmission, recommended personal protective equipment for health workers, and advocated testing, given the outbreak's "pandemic potential". On 31 January the first published modelling study warned of inevitable "independent self-sustaining outbreaks in major cities globally" and called for "large-scale public health interventions."
On 30 January, 7,818 infections had been confirmed, leading WHO to declare the outbreak a Public Health Emergency of International Concern (PHEIC). On 11 March, WHO elevated it to a pandemic.
By 31 January, Italy had its first confirmed infections, in two tourists from China. On 19 March, Italy overtook China as the country with the most reported deaths. By 26 March, the United States had overtaken China and Italy as the country with the highest number of confirmed infections. Genomic analysis indicated that the majority of New York's confirmed infections came from Europe, rather than directly from Asia. Testing of prior samples revealed a person who was infected in France on 27 December 2019 and a person in the United States who died from the disease on 6 February.
In April Russia sent a cargo plane with medical aid to the United States.
In October, WHO reported that one in ten people around the world may have been infected, or 780 million people, while only 35 million infections had been confirmed.
On 9 November, Pfizer released trial results for a candidate vaccine, showing a 90 per cent effectiveness against infection. That day, Novavax entered an FDA Fast Track application for their vaccine.
On 14 December, Public Health England reported that a variant had been discovered in the UK's southeast, predominantly in Kent. The variant, later named Alpha, showed changes to the spike protein that could be more infectious. As of 13 December, 1,108 infections had been confirmed.
On 2 January, the Alpha variant, first discovered in the UK, had been identified in 33 countries. On 6 January, the Gamma variant was first identified in Japanese travellers returning from Brazil. On 29 January, it was reported that the Novavax vaccine was 49 per cent effective against the Beta variant in a clinical trial in South Africa. The CoronaVac vaccine was reported to be 50.4 per cent effective in a Brazil clinical trial.
On 12 March, several countries stopped using the Oxford-AstraZeneca COVID-19 vaccine due to blood clotting problems, specifically cerebral venous sinus thrombosis (CVST). On 20 March, the WHO and European Medicines Agency found no link to thrombus, leading several countries to resume the vaccine. In March WHO reported that an animal host was the most likely origin, without ruling out other possibilities. The Delta variant was first identified in India. In mid-April, the variant was first detected in the UK and two months later it had metastasized into a third wave there, forcing the government to delay reopening that was originally scheduled for June.
On 10 November, Germany advised against the Moderna vaccine for people under 30. On 24 November, the Omicron variant was detected in South Africa; a few days later the World Health Organization declared it a VoC (variant of concern). The new variant is more infectious than the Delta variant.
On 6 March, it was reported that the total worldwide death count had surpassed 6 million people since the start of the pandemic.
National reactions ranged from strict lockdowns to public education campaigns. WHO recommended that curfews and lockdowns should be short-term measures to reorganise, regroup, rebalance resources, and protect the health care system. As of 26 March 2020, 1.7 billion people worldwide were under some form of lockdown. This increased to 3.9 billion people by the first week of April—more than half the world's population.
As of the end of 2021, Asia's peak had come at the same time and at the same level as the world as a whole, in May 2021. However, cumulatively they had experienced only half the world average.
China opted for containment, inflicting strict lockdowns to eliminate spread. The vaccines distributed in China included the BIBP, WIBP, and CoronaVac. It was reported on 11 December 2021 that China had vaccinated 1.162 billion of its citizens, or 82.5% of the total population of the country against COVID-19. During the initial outbreak, multiple sources cast doubt upon the accuracy of China's death tolls, with some suggesting intentional data suppression. China's large scale adoption of Zero-COVID had largely contained the first wave of infections of the disease, with external experts agreeing with the accuracy of China's infection numbers and deaths since the initial outbreak. China is almost alone in pursuing a Zero-Covid policy to combat the continuing wave of infections due to the Omicron variant in 2022.
The first case in India was reported on 30 January 2020. India ordered a nationwide lockdown starting 24 March 2020, with a phased unlock beginning 1 June 2020. Six cities accounted for around half of reported cases—Mumbai, Delhi, Ahmedabad, Chennai, Pune and Kolkata. Post-lockdown, the Government of India introduced a contact tracking app called Arogya Setu to help authorities manage contact tracing. Later this app was also used for a vaccination management program. India's vaccination program was considered to be the world's largest and the most successful with over 90% of citizens getting the first dose and another 65% getting the second dose. A second wave hit India in April 2021, straining healthcare services. On 21 October 2021, it was reported that the country had surpassed 1 billion vaccinations.
Iran reported its first confirmed cases on 19 February 2020 in Qom. Early measures included the cancellation of concerts and other cultural events, Friday prayers, and education shutdowns. Iran became a centre of the pandemic in February 2020. More than ten countries had traced their outbreaks to Iran by 28 February, indicating a more severe outbreak than the 388 reported cases. The Iranian Parliament closed, after 23 of its 290 members tested positive on 3 March 2020. At least twelve sitting or former Iranian politicians and government officials had died by 17 March 2020. By August 2021, the pandemic's fifth wave peaked, with more than 400 deaths in 1 day.
COVID-19 was confirmed in South Korea on 20 January 2020. Military bases were quarantined after tests showed three infected soldiers. South Korea introduced what was then considered the world's largest and best-organised screening programme, isolating infected people, and tracing and quarantining contacts. Screening methods included mandatory self-reporting by new international arrivals through mobile application, combined with drive-through testing, and increasing testing capability to 20,000 people/day. Despite some early criticisms, South Korea's programme was considered a success in controlling the outbreak without quarantining entire cities.
The global COVID-19 pandemic arrived in Europe with its first confirmed case in Bordeaux, France, on 24 January 2020, and subsequently spread widely across the continent. By 17 March 2020, every country in Europe had confirmed a case, and all have reported at least one death, with the exception of Vatican City. Italy was the first European nation to experience a major outbreak in early 2020, becoming the first country worldwide to introduce a national lockdown. By 13 March 2020, the World Health Organization (WHO) declared Europe the epicentre of the pandemic and it remained so until the WHO announced it has been overtaken by South America on 22 May. By 18 March 2020, more than 250 million people were in lockdown in Europe. Despite deployment of COVID-19 vaccines, Europe became the pandemic's epicentre once again in late 2021.
The Italian outbreak began on 31 January 2020, when two Chinese tourists tested positive for SARS-CoV-2 in Rome. Cases began to rise sharply, which prompted the government to suspend flights to and from China and declare a state of emergency. On 22 February 2020, the Council of Ministers announced a new decree-law to contain the outbreak, including quarantining more than 50,000 people in northern Italy. On 4 March the Italian government ordered schools and universities closed as Italy reached a hundred deaths. Sport was suspended completely for at least one month. On 11 March Conte stopped nearly all commercial activity except supermarkets and pharmacies. On 19 March Italy overtook China as the country with the most COVID-19-related deaths. On 19 April the first wave ebbed, as 7-day deaths declined to 433. On 13 October, the Italian government again issued restrictive rules to contain the second wave. On 10 November Italy surpassed 1 million confirmed infections. On 23 November, it was reported that the second wave of the virus had led some hospitals to stop accepting patients.
The virus was first confirmed to have spread to Spain on 31 January 2020, when a German tourist tested positive for SARS-CoV-2 in La Gomera, Canary Islands. Post-hoc genetic analysis has shown that at least 15 strains of the virus had been imported, and community transmission began by mid-February. On 29 March, it was announced that, beginning the following day, all non-essential workers were ordered to remain at home for the next 14 days. The number of cases increased again in July in a number of cities including Barcelona, Zaragoza and Madrid, which led to reimposition of some restrictions but no national lockdown. By September 2021, Spain was one of the countries with the highest per centage of its population vaccinated (76% fully vaccinated and 79% with the first dose), while also being one of the countries more in favour of vaccines against COVID-19 (nearly 94% of its population were already vaccinated or wanted to be). However, as of 21 January 2022, this figure had only increased to 80.6%. Nevertheless, Spain leads Europe for per-capita full-vaccination rates. Italy is ranked 2nd at 75%.
Sweden differed from most other European countries in that it mostly remained open. Per the Swedish Constitution, the Public Health Agency of Sweden has autonomy that prevents political interference and the agency favoured remaining open. The Swedish strategy focused on longer-term measures, based on the assumption that after lockdown the virus would resume spreading, with the same result. By the end of June, Sweden no longer had excess mortality.
Devolution in the United Kingdom meant that each of its four countries developed its own response. England's restrictions were shorter-lived than the others. The UK government started enforcing social distancing and quarantine measures on 18 March 2020. On 16 March, Prime Minister Boris Johnson advised against non-essential travel and social contact, praising work from home and avoiding venues such as pubs, restaurants, and theatres. On 20 March, the government ordered all leisure establishments to close, and promised to prevent unemployment. On 23 March, Johnson banned gatherings and restricted non-essential travel and outdoor activity. Unlike previous measures, these restrictions were enforceable by police through fines and dispersal of gatherings. Most non-essential businesses were ordered to close. On 24 April 2020, it was reported that a promising vaccine trial had begun in England; the government pledged more than £50 million towards research. On 16 April 2020, it was reported that the UK would have first access to the Oxford vaccine, due to a prior contract; should the trial be successful, some 30 million doses would be available. On 2 December 2020, the UK became the first developed country to approve the Pfizer vaccine; 800,000 doses were immediately available for use.
The virus arrived in the United States on 13 January 2020. Cases were reported in all North American countries after Saint Kitts and Nevis confirmed a case on 25 March, and in all North American territories after Bonaire confirmed a case on 16 April.
86,949,088 confirmed cases have been reported in the United States with 1,015,933 deaths, the most of any country, and the nineteenth-highest per capita worldwide. COVID-19 is the deadliest pandemic in U.S. history; it was the third-leading cause of death in the U.S. in 2020, behind heart disease and cancer. From 2019 to 2020, U.S. life expectancy dropped by 3 years for Hispanic Americans, 2.9 years for African Americans, and 1.2 years for white Americans. These effects have persisted as U.S. deaths due to COVID-19 in 2021 exceeded those in 2020. In the United States, COVID-19 vaccines became available in December 2020, under emergency use, beginning the national vaccination program, with the first vaccine officially approved by the Food and Drug Administration (FDA) on 23 August 2021.
In March 2020, as cases of community transmission were confirmed across Canada, all of its provinces and territories declared states of emergency. Provinces and territories have, to varying degrees, implemented school and daycare closures, prohibitions on gatherings, closures of non-essential businesses and restrictions on entry. Canada severely restricted its border access, barring travellers from all countries with some exceptions. Cases surged across Canada, notably in the provinces of British Columbia, Alberta, Quebec and Ontario, with the formation of the Atlantic Bubble, a travel-restricted area of the country (formed of the four Atlantic provinces). Vaccine passports were adopted in all provinces and two of the territories.
The COVID-19 pandemic was confirmed to have reached South America on 26 February 2020 when Brazil confirmed a case in São Paulo. By 3 April, all countries and territories in South America had recorded at least one case. On 13 May 2020, it was reported that Latin America and the Caribbean had reported over 400,000 cases of COVID-19 infection with 23,091 deaths. On 22 May 2020, citing the rapid increase of infections in Brazil, the World Health Organization WHO declared South America the epicentre of the pandemic. As of 16 July 2021, South America had recorded 34,359,631 confirmed cases and 1,047,229 deaths from COVID-19. Due to a shortage of testing and medical facilities, it is believed that the outbreak is far larger than the official numbers show.
The virus was confirmed to have spread to Brazil on 25 February 2020, when a man from São Paulo who had traveled to Italy tested positive for the virus. The disease had spread to every federative unit of Brazil by 21 March. On 19 June 2020, the country reported its one millionth case and nearly 49,000 reported deaths. One estimate of under-reporting was 22.62% of total reported COVID-19 mortality in 2020. As of 26 June 2022, Brazil, with 32,023,166 confirmed cases and 670,229 deaths, has the third-highest number of confirmed cases and second-highest death toll from COVID-19 in the world, behind only those of the United States and of India.
The COVID-19 pandemic was confirmed to have spread to Africa on 14 February 2020, with the first confirmed case announced in Egypt. The first confirmed case in sub-Saharan Africa was announced in Nigeria at the end of February 2020. Within three months, the virus had spread throughout the continent, as Lesotho, the last African sovereign state to have remained free of the virus, reported a case on 13 May 2020. By 26 May, it appeared that most African countries were experiencing community transmission, although testing capacity was limited. Most of the identified imported cases arrived from Europe and the United States rather than from China where the virus originated. Many preventive measures have been implemented by different countries in Africa including travel restrictions, flight cancellations, and event cancellations.
In early June 2021, Africa faced a third wave of COVID infections with cases rising in 14 countries. By 4 July the continent recorded more than 251,000 new COVID cases, a 20% increase from the prior week and a 12% increase from the January peak. More than sixteen African countries, including Malawi and Senegal, recorded an uptick in new cases. The World Health Organization labelled it Africa's 'Worst Pandemic Week Ever'.
The COVID-19 pandemic was confirmed to have reached Oceania on 25 January 2020 with the first confirmed case reported in Melbourne, Australia. It has since spread elsewhere in the region, although many small Pacific island nations have thus far avoided the outbreak by closing their international borders. Two Oceania sovereign states (Nauru and Tuvalu) and one dependency (Cook Islands) have yet to report an active case. Australia and New Zealand were praised for their handling of the pandemic in comparison to other Western nations, with New Zealand and each state in Australia wiping out all community transmission of the virus several times even after re-introduction into the community.
As a result of the high transmissibility of the Delta variant, however, by August 2021, the Australian states of New South Wales and Victoria had conceded defeat in their eradication efforts. In early October 2021, New Zealand also abandoned its elimination strategy. In November and December, following vaccination efforts, the remaining states of Australia, excluding Western Australia, voluntarily gave up COVID-zero to open up state and international borders. The open borders allowed the Omicron Variant of COVID-19 to enter quickly and cases subsequently exceeded 120,000 a day. By early March, with cases exceeding 1000 a day Western Australia conceded defeat in its eradication stratergy and opened the borders after previously delaying the re-opening due to the omicron variant. Despite record cases, Australian jurisdictions slowly removed restrictions such as close contact isolation, mask wearing and density limits, with Western Australia the last to remove restrictions on 26 April.
Due to its remoteness and sparse population, Antarctica was the last continent to have confirmed cases of COVID-19 and was one of the last regions of the world affected directly by the pandemic. The first cases were reported in December 2020, almost a year after the first cases of COVID-19 were detected in China. At least 36 people are confirmed to have been infected.
The pandemic shook the world's economy, with especially severe economic damage in the United States, Europe, and Latin America. A consensus report by American intelligence agencies in April 2021 concluded, "Efforts to contain and manage the virus have reinforced nationalist trends globally, as some states turned inward to protect their citizens and sometimes cast blame on marginalized groups." COVID-19 inflamed partisanship and polarisation around the world as bitter arguments exploded over how to respond. International trade was disrupted amid the formation of no-entry enclaves.
The pandemic led many countries and regions to impose quarantines, entry bans, or other restrictions, either for citizens, recent travellers to affected areas, or for all travellers. Travel collapsed worldwide, damaging the travel sector. The effectiveness of travel restrictions was questioned as the virus spread across the world. One study found that travel restrictions only modestly affected the initial spread, unless combined with other infection prevention and control measures. Researchers concluded that "travel restrictions are most useful in the early and late phase of an epidemic" and "restrictions of travel from Wuhan unfortunately came too late".
Repatriation of foreign citizens
Several countries repatriated their citizens and diplomatic staff from Wuhan and surroundings, primarily through charter flights. Canada, the United States, Japan, India, Sri Lanka, Australia, France, Argentina, Germany, and Thailand were among the first to do so. Brazil and New Zealand evacuated their own nationals and others. On 14 March, South Africa repatriated 112 South Africans who tested negative, while four who showed symptoms were left behind. Pakistan declined to evacuate its citizens.
On 15 February, the US announced it would evacuate Americans aboard the Diamond Princess cruise ship, and on 21 February, Canada evacuated 129 Canadians from the ship. In early March, the Indian government began repatriating its citizens from Iran. On 20 March, the United States began to withdraw some troops from Iraq.
In June 2020, the Secretary-General of the United Nations launched the UN Comprehensive Response to COVID-19. The United Nations Conference on Trade and Development (UNSC) was criticised for its slow response, especially regarding the UN's global ceasefire, which aimed to open up humanitarian access to conflict zones.
The WHO spearheaded initiatives such as the COVID-19 Solidarity Response Fund to raise money for the pandemic response, the UN COVID-19 Supply Chain Task Force, and the solidarity trial for investigating potential treatment options for the disease. The COVAX program, co-led by the WHO, GAVI, and the Coalition for Epidemic Preparedness Innovations (CEPI), aimed to accelerate the development, manufacture, and distribution of COVID-19 vaccines, and to guarantee fair and equitable access across the world.
Protests against governmental measures
In several countries, protests rose against restrictions such as lockdowns. A February 2021 study found that protests against restrictions were likely to directly increase spread.
The pandemic and responses to it damaged the global economy. On 27 February 2020, worries about the outbreak crushed US stock indexes, which posted their sharpest falls since 2008.
Tourism collapsed due to travel restrictions, closing of public places including travel attractions, and advice of governments against travel. Airlines cancelled flights, while British regional airline Flybe collapsed. The cruise line industry was hard hit, and train stations and ferry ports closed. International mail stopped or was delayed.
The retail sector faced reductions in store hours or closures. Retailers in Europe and Latin America faced traffic declines of 40 per cent. North America and Middle East retailers saw a 50–60 per cent drop. Shopping centres faced a 33–43 per cent drop in foot traffic in March compared to February. Mall operators around the world coped by increasing sanitation, installing thermal scanners to check the temperature of shoppers, and cancelling events.
The outbreak was blamed for panic buying, emptying groceries of essentials such as food, toilet paper, and bottled water. Panic buying stemmed from perceived threat, perceived scarcity, fear of the unknown, coping behaviour and social psychological factors (e.g. social influence and trust).
Shortages continued as managers underestimated the speed of economic recovery after the initial economic crash. The technology industry, in particular, warned of delays from underestimates of semiconductor demand for vehicles and other products.
In September 2021, the World Bank reported that food prices remain generally stable and the supply outlook remains positive. However, the poorest countries witnessed a sharp increase in food prices, reaching the highest level since the pandemic began. The Agricultural Commodity Price Index stabilized in the third quarter but remained 17% higher than in January 2021.
By contrast, petroleum products were in surplus at the beginning of the pandemic, as demand for gasoline and other products collapsed due to reduced commuting and other trips. The 2021 global energy crisis was driven by a global surge in demand as the world economy recovered. Energy demand was particularly strong in Asia.
The performing arts and cultural heritage sectors have been profoundly affected by the pandemic, impacting organisations' operations as well as individuals—both employed and independent—globally. By March 2020, across the world and to varying degrees, museums, libraries, performance venues, and other cultural institutions had been indefinitely closed with their exhibitions, events and performances cancelled or postponed. A UNESCO report estimated ten million job losses worldwide in the culture and creative industries. Some services continued through digital platforms, such as live streaming concerts or web-based arts festivals.
Although they developed broad support among epidemiologists, NPIs (non-pharmaceutical interventions) were controversial in many countries. Intellectual opposition came primarily from other fields, along with heterodox epidemiologists.
On 23 March 2020, United Nations Secretary-General António Manuel de Oliveira Guterres appealed for a global ceasefire; 172 UN member states and observers signed a non-binding supporting statement in June, and the UN Security Council passed a resolution supporting it in July.
Multiple provincial-level administrators of the Chinese Communist Party were dismissed over their handling of quarantine measures. Some commentators claimed this move was intended to protect CCP general secretary Xi Jinping. The US intelligence community claimed that China intentionally under-reported its COVID-19 caseload. The Chinese government maintained that it acted swiftly and transparently. Journalists and activists in China who reported on the pandemic were detained by authorities, including Zhang Zhan, who was arrested and tortured.
In early March 2020, the Italian government criticised the EU's lack of solidarity with Italy. On 22 March 2020, after a phone call with Italian Prime Minister Giuseppe Conte, Russian president Vladimir Putin ordered the Russian army to send military medics, disinfection vehicles, and other medical equipment to Italy. In early April, Norway and EU states like Romania and Austria started to offer help by sending medical personnel and disinfectant, and Ursula von der Leyen offered an official apology to the country.
Beginning in mid-April 2020, protestors objected to government-imposed business closures and restricted personal movement and association. Simultaneously, essential workers protested in the form of a brief general strike. Some political analysts claimed that the pandemic contributed to President Donald Trump's 2020 defeat.
The outbreak prompted calls for the United States to adopt social policies common in other wealthy countries, including universal health care, universal child care, paid sick leave, and higher levels of funding for public health. The cost of preventable hospitalizations (of unvaccinated people) for COVID-19 in the United States between June and November 2021 has been estimated at US$13.8 billion.
The Iranian government was heavily affected by the virus, which infected some two dozen parliament members and political figures. Iran President Hassan Rouhani wrote a public letter to world leaders asking for help on 14 March 2020, due to a lack of access to international markets. Saudi Arabia, which launched a military intervention in Yemen in March 2015, declared a ceasefire.
Diplomatic relations between Japan and South Korea worsened. South Korea criticised Japan's "ambiguous and passive quarantine efforts" after Japan announced travellers from South Korea must quarantine for two weeks. South Korean society was initially polarised on President Moon Jae-in's response to the crisis; many Koreans signed petitions calling for Moon's impeachment or praising his response.
Some countries passed emergency legislation. Some commentators expressed concern that it could allow governments to strengthen their grip on power. In the Philippines, lawmakers granted President Rodrigo Duterte temporary emergency powers. In Hungary, the parliament voted to allow prime minister Viktor Orbán to rule by decree indefinitely, suspend parliament and elections, and punish those deemed to have spread false information. In countries such as Egypt, Turkey, and Thailand, opposition activists and government critics were arrested for allegedly spreading fake news.
In India, journalists criticising the government's response were arrested or issued warnings by police and authorities.
The pandemic disrupted food systems worldwide, hitting at a time when hunger/undernourishment was rising (an estimated 690 million people lacked food security in 2019). Food access fell – driven by falling incomes, lost remittances, and disruptions to food production. In some cases, food prices rose.
The pandemic and its accompanying lockdowns and travel restrictions slowed movement of food aid. Per the World Health Organization 811 million individuals were undernourished in 2020, "likely related to the fallout of COVID-19".
The pandemic impacted educational systems in many countries. Many governments temporarily closed educational institutions, often replaced by online education. Other countries, such as Sweden, kept their schools open. As of September 2020, approximately 1.077 billion learners were affected due to school closures. School closures impacted students, teachers, and families with far-reaching economic and societal consequences. They shed light on social and economic issues, including student debt, digital learning, food insecurity, and homelessness, as well as access to childcare, health care, housing, internet, and disability services. The impact was more severe for disadvantaged children.
The Higher Education Policy Institute reported that around 63% of students claimed worsened mental health as a result of the pandemic.
The pandemic impacted global health for many other conditions. Hospital visits fell. Visits for heart attack symptoms declined by 38% in the US and 40% in Spain. The head of cardiology at the University of Arizona said, "My worry is some of these people are dying at home because they're too scared to go to the hospital." People with strokes and appendicitis were less likely to seek treatment. Medical supply shortages impacted many people.
The pandemic and the reaction to it positively affected the environment and climate as a result of reduced human activity. During the "anthropause", fossil fuel use decreased, resource consumption declined, and waste disposal improved, generating less pollution. Planned air travel and vehicle transportation declined. In China, lockdowns and other measures resulted in a 26% decrease in coal consumption, and a 50% reduction in nitrogen oxides emissions. Earth systems scientist Marshall Burke estimated that two months of pollution reduction likely saved the lives of 53,000 to 77,000 Chinese residents.
Discrimination and prejudice
Heightened prejudice, xenophobia, and racism toward people of Chinese and East Asian descent were documented around the world. Reports from February 2020 (when most confirmed cases were confined to China) cited racist sentiments about Chinese people 'deserving' the virus. Chinese people and other Asian peoples in the United Kingdom and United States reported increasing levels of abuse and assaults. Former US President Trump was criticised for referring to SARS-CoV-2 as the "Chinese Virus" and "Kung Flu", which others condemned as racist and xenophobic.
Age-based discrimination against older adults increased. This was attributed to their perceived vulnerability and subsequent physical and social isolation measures, which, coupled with their reduced social activity, increased dependency on others. Similarly, limited digital literacy left the elderly more vulnerable to isolation, depression, and loneliness.
The pandemic triggered massive changes in behaviour, from increased Internet commerce to cultural changes in the job market. Online retailers in the US posted US$791.70 billion in sales in 2020, an increase of 32.4% from $598.02 billion from the year before. Home delivery orders increased, while indoor restaurant dining shut down due to lockdown orders or low sales. Hackers, cybercriminals, and scammers took advantage of the changes to launch new attacks. Education in some countries temporarily shifted from physical attendance to video conferencing. Massive layoffs shrank the airline, travel, hospitality, and other industries.
Research is indexed and searchable in the NIH COVID-19 Portfolio. Some newspaper agencies removed their online paywalls for some or all of their pandemic-related articles and posts. Some scientific publishers made pandemic-related papers available with open access. The share of papers published on preprint servers prior to peer review increased dramatically.
Misinformation and conspiracy theories about the pandemic are widespread. They travelled through mass media, social media, and text messaging. WHO declared an "infodemic" of incorrect information. Cognitive biases, such as jumping to conclusions and confirmation bias, were linked to conspiracy beliefs.
Transition to endemic phase
In June 2022, an article in Human Genomics said that "now is the time to explore the transition from the pandemic to the endemic phase. The latter will require worldwide vigilance and cooperation, especially in emerging countries", and suggested that developed countries should assist in boosting vaccination rates worldwide.
- Some refer to 'fatality rate'; however 'fatality ratio' is more accurate as this is not per unit time.
- Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos DA (October 2020). "[Comment] The COVID‑19 pandemic as a scientific and social challenge in the 21st century". Molecular Medicine Reports. 22 (4): 3035–3048. doi:10.3892/mmr.2020.11393. PMC 7453598. PMID 32945405.
- "WHO-convened global study of origins of SARS-CoV-2: China Part". World Health Organization. 30 March 2021. Retrieved 31 March 2021.
- "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 25 June 2022.
- "The pandemic's true death toll". The Economist. Retrieved 4 May 2022.
- CDC (11 February 2020). "COVID-19 and Your Health". Centers for Disease Control and Prevention. Retrieved 6 January 2022.
- Clinical Questions about COVID‑19: Questions and Answers US Centers for Disease Control and Prevention
- Office of the Commissioner (23 November 2020). "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". FDA. Retrieved 19 December 2021.
- "The Great Lockdown: Worst Economic Downturn Since the Great Depression". IMF Blog. Retrieved 23 April 2020.
- Multiple sources:
- "Coronavirus – The latest news on the COVID-19 outbreak". Sky News. Retrieved 20 July 2021.
- "Coronavirus News – BBC News". BBC News. Retrieved 20 July 2021.
- "Coronavirus (COVID-19)". nhs.uk. 2 June 2020. Retrieved 20 July 2021.
- Coronavirus: the science explained-UKRI. "What is coronavirus? The different types of coronaviruses". coronavirusexplained.ukri.org. Retrieved 20 July 2021.
- Multiple sources:
- "2nd U.S. Case Of Wuhan Coronavirus Confirmed". NPR.org. NPR. Retrieved 4 April 2020.
- McNeil Jr DG (2 February 2020). "Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say". The New York Times. ISSN 0362-4331. Retrieved 4 April 2020.
- Griffiths J. "Wuhan coronavirus deaths spike again as outbreak shows no signs of slowing". CNN. Retrieved 4 April 2020.
- Zhu H, Wei L, Niu P (2 March 2020). "The novel coronavirus outbreak in Wuhan, China". Global Health Research and Policy. 5 (1): 6. doi:10.1186/s41256-020-00135-6. PMC 7050114. PMID 32226823.
- Jiang S, Xia S, Ying T, Lu L (May 2020). "A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome". Cellular & Molecular Immunology. 17 (5): 554. doi:10.1038/s41423-020-0372-4. PMC 7091741. PMID 32024976.
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. (February 2020). "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster". Lancet. 395 (10223): 514–523. doi:10.1016/S0140-6736(20)30154-9. PMC 7159286. PMID 31986261.
- "Novel Coronavirus (2019-nCoV) Situation Report – 1" (PDF). World Health Organization (WHO). 21 January 2020.
- "Novel Coronavirus(2019-nCoV) Situation Report – 10" (PDF). World Health Organization (WHO). 30 January 2020.
- Multiple sources:
- "Novel coronavirus named 'Covid-19': WHO". Today. Singapore. Archived from the original on 21 March 2020. Retrieved 11 February 2020.
- "The coronavirus spreads racism against – and among – ethnic Chinese". The Economist. 17 February 2020. Archived from the original on 17 February 2020. Retrieved 17 February 2020.
- World Health Organization Best Practices for the Naming of New Human Infectious Diseases (PDF) (Report). World Health Organization (WHO). May 2015. hdl:10665/163636.
- "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO). Archived from the original on 28 February 2020. Retrieved 13 March 2020.
- Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – eighth update (PDF) (Report). ecdc. Archived (PDF) from the original on 14 March 2020. Retrieved 19 April 2020.
- "Covid Indian variant: Where is it, how does it spread and is it more infectious?". BBC News. 7 June 2021. Retrieved 20 July 2021.
- "Covid: WHO renames UK and other variants with Greek letters". BBC News. 31 May 2021. Retrieved 8 June 2021.
- Patel V (27 November 2021). "How Omicron, the New Covid-19 Variant, Got Its Name". The New York Times. ISSN 0362-4331. Archived from the original on 28 November 2021. Retrieved 28 November 2021.
- "There are several COVID-19 variants you haven't heard of". NewsNation Now. 27 November 2021. Archived from the original on 27 November 2021. Retrieved 27 November 2021.
- Perlman S (February 2020). "Another Decade, Another Coronavirus". The New England Journal of Medicine. 382 (8): 760–762. doi:10.1056/NEJMe2001126. PMC 7121143. PMID 31978944.
- Cyranoski D (March 2020). "Mystery deepens over animal source of coronavirus". Nature. 579 (7797): 18–19. Bibcode:2020Natur.579...18C. doi:10.1038/d41586-020-00548-w. PMID 32127703. S2CID 211836524.
- Zhang T, Wu Q, Zhang Z (April 2020). "Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak". Current Biology. 30 (7): 1346–1351.e2. doi:10.1016/j.cub.2020.03.022. PMC 7156161. PMID 32197085.
- "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2): increased transmission beyond China – fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
- Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. (May 2020). "COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives". Trends in Molecular Medicine. 26 (5): 483–495. doi:10.1016/j.molmed.2020.02.008. PMC 7118693. PMID 32359479.
- "WHO Points To Wildlife Farms In Southern China As Likely Source Of Pandemic". NPR. 15 March 2021.
- Maxmen A (April 2021). "WHO report into COVID pandemic origins zeroes in on animal markets, not labs". Nature. 592 (7853): 173–174. Bibcode:2021Natur.592..173M. doi:10.1038/d41586-021-00865-8. PMID 33785930. S2CID 232429241.
- Hu B, Guo H, Zhou P, Shi ZL (March 2021). "Characteristics of SARS-CoV-2 and COVID-19". Nature Reviews. Microbiology. 19 (3): 141–154. doi:10.1038/s41579-020-00459-7. PMC 7537588. PMID 33024307.
- Graham RL, Baric RS (May 2020). "SARS-CoV-2: Combating Coronavirus Emergence". Immunity. 52 (5): 734–736. doi:10.1016/j.immuni.2020.04.016. PMC 7207110. PMID 32392464.
- Multiple sources:
- "The COVID-19 coronavirus epidemic has a natural origin, scientists say – Scripps Research's analysis of public genome sequence data from SARS‑CoV‑2 and related viruses found no evidence that the virus was made in a laboratory or otherwise engineered". EurekAlert!. Scripps Research Institute. 17 March 2020. Retrieved 15 April 2020.
- Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615.
- Latinne A, Hu B, Olival KJ, Zhu G, Zhang L, Li H, et al. (August 2020). "Origin and cross-species transmission of bat coronaviruses in China". Nature Communications. 11 (1): 4235. Bibcode:2020NatCo..11.4235L. doi:10.1038/s41467-020-17687-3. PMC 7447761. PMID 32843626.
- Fox M (7 July 2021). "Coronavirus almost certainly came from an animal, not a lab leak, top scientists argue". CNN. Retrieved 9 July 2021.
- "Market in China's Wuhan likely origin of COVID-19 outbreak – study". Reuters. 19 November 2021. Retrieved 19 November 2021.
- To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, et al. (March 2021). "Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic". Emerging Microbes & Infections. 10 (1): 507–535. doi:10.1080/22221751.2021.1898291. PMC 8006950. PMID 33666147.
- Hakim MS (February 2021). "SARS-CoV-2, Covid-19, and the debunking of conspiracy theories". Reviews in Medical Virology. 31 (6): e2222. doi:10.1002/rmv.2222. PMC 7995093. PMID 33586302.
- Qin A, Wang V, Hakim D (20 November 2020). "How Steve Bannon and a Chinese Billionaire Created a Right-Wing Coronavirus Media Sensation". The New York Times. Archived from the original on 30 April 2021.
- Multiple sources:
- Frutos R, Gavotte L, Devaux CA (March 2021). "Understanding the origin of COVID-19 requires to change the paradigm on zoonotic emergence from the spillover to the circulation model". Infection, Genetics and Evolution. 95: 104812. doi:10.1016/j.meegid.2021.104812. PMC 7969828. PMID 33744401.
The origin of SARS-Cov-2 is still passionately debated since it makes ground for geopolitical confrontations and conspiracy theories besides scientific ones.
- Maxmen A (27 May 2021). "Divisive COVID 'lab leak' debate prompts dire warnings from researchers". Nature. 594 (7861): 15–16. Bibcode:2021Natur.594...15M. doi:10.1038/d41586-021-01383-3. PMID 34045757. S2CID 235232290.
- Ni V, Borger J (27 May 2021). "Biden move to investigate Covid origins opens new rift in US-China relations". The Guardian.
- Frutos R, Gavotte L, Devaux CA (March 2021). "Understanding the origin of COVID-19 requires to change the paradigm on zoonotic emergence from the spillover to the circulation model". Infection, Genetics and Evolution. 95: 104812. doi:10.1016/j.meegid.2021.104812. PMC 7969828. PMID 33744401.
- Cohen J (January 2020). "Wuhan seafood market may not be source of novel virus spreading globally". Science. doi:10.1126/science.abb0611. S2CID 214574620.
- Wang C, Horby PW, Hayden FG, Gao GF (February 2020). "A novel coronavirus outbreak of global health concern". Lancet. 395 (10223): 470–473. doi:10.1016/S0140-6736(20)30185-9. PMC 7135038. PMID 31986257.
- Ma J (13 March 2020). "Coronavirus: China's first confirmed Covid-19 case traced back to November 17". South China Morning Post. Archived from the original on 13 March 2020. Retrieved 16 March 2020.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264.
- Joseph A (24 January 2020). "New coronavirus can cause infections with no symptoms and sicken otherwise healthy people, studies show". Stat. Archived from the original on 24 January 2020. Retrieved 27 January 2020.
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. (February 2020). "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster". Lancet. 395 (10223): 514–523. doi:10.1016/S0140-6736(20)30154-9. PMC 7159286. PMID 31986261.
- Pekar J, Worobey M, Moshiri N, Scheffler K, Wertheim JO (April 2021). "Timing the SARS-CoV-2 index case in Hubei province". Science. 372 (6540): 412–417. Bibcode:2021Sci...372..412P. doi:10.1126/science.abf8003. PMC 8139421. PMID 33737402.
- To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, et al. (December 2021). "Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic". Emerging Microbes & Infections. 10 (1): 507–535. doi:10.1080/22221751.2021.1898291. PMC 8006950. PMID 33666147.
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Retrieved 30 March 2020.
- "Total tests for COVID-19 per 1,000 people". Our World in Data. Retrieved 16 April 2020.
- "Report 13 – Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries". Imperial College London. Retrieved 7 April 2020.
- Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Ichii H, Schubert J, et al. (June 2020). "Internationally lost COVID-19 cases". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 53 (3): 454–458. doi:10.1016/j.jmii.2020.03.013. PMC 7102572. PMID 32205091.
- Sevillano EG, Linde P, Vizoso S (23 March 2020). "640,000 rapid coronavirus tests arrive in Spain". El País. Retrieved 2 April 2020.
- Parodi E, Jewkes S, Cha S, Park JM (12 March 2020). "Special Report: Italy and South Korea virus outbreaks reveal disparity in deaths and tactics". Reuters. Archived from the original on 12 March 2020. Retrieved 11 May 2022.
- Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. (July 2021). "Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020 – March 2021". Preventing Chronic Disease. Centers for Disease Control and Prevention. 18: E66. doi:10.5888/pcd18.210123. PMC 8269743. PMID 34197283.
- "China: age distribution of novel coronavirus patients 2020". Statista. Retrieved 11 April 2020.
- Scott D (23 March 2020). "The Covid-19 risks for different age groups, explained". Vox. Retrieved 12 April 2020.
- Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. (August 2020). "Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study". The Lancet. Infectious Diseases. 20 (8): 911–919. doi:10.1016/S1473-3099(20)30287-5. PMC 7185944. PMID 32353347.
- Streeck H (9 April 2020). "Vorläufiges Ergebnis und Schlussfolgerungen der COVID-19 Case-Cluster-Study (Gemeinde Gangelt)" (PDF). Land NRW – State of North Rhine-Westphalia. Retrieved 13 April 2020.
- Sutton D, Fuchs K, D'Alton M, Goffman D (May 2020). "Universal Screening for SARS-CoV-2 in Women Admitted for Delivery". The New England Journal of Medicine. 382 (22): 2163–2164. doi:10.1056/NEJMc2009316. PMC 7175422. PMID 32283004.
- "Dutch study suggests 3% of population may have coronavirus antibodies". Reuters. 16 April 2020. Retrieved 20 April 2020.
- "Interactive Serology Dashboard for Commercial Laboratory Surveys". Centres for Disease Control and Prevention. 21 July 2020. Retrieved 24 July 2020.
- "Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus 2019 (n-CoV) on 23 January 2020". World Health Organization (WHO). Retrieved 9 April 2020.
- Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R (July 2020). "High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2". Emerging Infectious Diseases. 26 (7): 1470–1477. doi:10.3201/eid2607.200282. PMC 7323562. PMID 32255761. S2CID 215410037.
- "ArcGIS Dashboards". gisanddata.maps.arcgis.com. Retrieved 22 December 2021.
- B K, Mazumder A (14 April 2022). "Worldwide COVID cases surpass 500 mln as Omicron variant BA.2 surges". Reuters. Retrieved 21 April 2022.
- "COVID-19 Results Briefing" (PDF). healthdata.org. Retrieved 7 February 2022.
- "COVID Evaluation Model Estimates 57 Percent of World Population Infected at Least Once". MSN. Retrieved 7 February 2022.
- "COVID-19/csse_covid_19_data/csse_covid_19_time_series at master · CSSEGISandData/COVID-19". GitHub. Retrieved 18 January 2022.
- "Coronavirus Death Toll Climbs in China, and a Lockdown Widens". The New York Times. 23 January 2020. Archived from the original on 6 February 2020. Retrieved 10 February 2020.
- Multiple sources:
- "The Best Global Responses to the COVID-19 Pandemic". Time. Retrieved 18 August 2020.
- Barrio PL, del Javier M (11 May 2020). "Portugal and Spain: same peninsula, very different coronavirus impact". El País. Retrieved 25 May 2020.
- Johnson M (5 April 2020). "Fewer deaths in Veneto offer clues for fight against virus". Financial Times. Retrieved 25 May 2020.
- Ritchie H, Roser M (25 March 2020). Chivers T (ed.). "What do we know about the risk of dying from COVID-19?". Our World in Data. Retrieved 28 March 2020.
- "Principles of Epidemiology | Lesson 3 – Section 3". US Centers for Disease Control and Prevention (CDC). 18 February 2019. Retrieved 28 March 2020.
- "Italy's coronavirus deaths could be underestimated in data: Official". Reuters. 31 March 2020.
- "Coronavirus: Is Covid-19 really the cause of all the fatalities in Italy?". Stuff. 20 March 2020. Retrieved 16 April 2020.
- Schultz T (22 April 2020). "Why Belgium's Death Rate Is So High: It Counts Lots Of Suspected COVID-19 Cases". NPR. Retrieved 25 April 2020.
- "Tracking covid-19 excess deaths across countries". The Economist. Retrieved 9 March 2022.
- "COVID-19 Projections". Institute for Health Metrics and Evaluation. Retrieved 20 January 2022.
- Wang, Haidong; et al. (April 2022). "Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21". Lancet. 399 (10334): 1513–1536. doi:10.1016/S0140-6736(21)02796-3. PMC 8912932. PMID 35279232.
News article about the study: Adam D (March 2022). "COVID's true death toll: much higher than official records". Nature. 603 (7902): 562. Bibcode:2022Natur.603..562A. doi:10.1038/d41586-022-00708-0. PMID 35277684. S2CID 247407282.
- "What 'Excess Deaths' Do and Don't Tell Us About COVID-19". Reason. 29 April 2020. Retrieved 4 May 2020.
- Grimley, Naomi; Cornish, Jack; Stylianou, Nassos (5 May 2022). "Covid: World's true pandemic death toll nearly 15 million, says WHO". BBC News.
- Rothan HA, Byrareddy SN (May 2020). "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak". Journal of Autoimmunity. 109: 102433. doi:10.1016/j.jaut.2020.102433. PMC 7127067. PMID 32113704.
- Yanez ND, Weiss NS, Romand JA, Treggiari MM (November 2020). "COVID-19 mortality risk for older men and women". BMC Public Health. 20 (1): 1742. doi:10.1186/s12889-020-09826-8. PMC 7675386. PMID 33213391.
- "People with Certain Medical Conditions". Centers for Disease Control and Prevention. 15 March 2021. Retrieved 19 March 2021.
- Covid: World’s true pandemic death toll nearly 15 million, says WHO BBC
- Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G (December 2020). "Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications". European Journal of Epidemiology. 35 (12): 1123–1138. doi:10.1007/s10654-020-00698-1. PMC 7721859. PMID 33289900.
- Tate N. "What Changing Death Rates Tell Us About COVID-19". WebMD. Retrieved 19 September 2020.
- "Estimating mortality from COVID-19". World Health Organization. 4 August 2020. Retrieved 21 September 2020.
- CDC (11 February 2020). "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. Retrieved 19 September 2020.
- Multiple sources:
- Mallapaty S (June 2020). "How deadly is the coronavirus? Scientists are close to an answer". Nature. 582 (7813): 467–468. Bibcode:2020Natur.582..467M. doi:10.1038/d41586-020-01738-2. PMID 32546810. S2CID 219726496.
- Alwan NA, Burgess RA, Ashworth S, Beale R, Bhadelia N, Bogaert D, et al. (October 2020). "Scientific consensus on the COVID-19 pandemic: we need to act now". Lancet. 396 (10260): e71–e72. doi:10.1016/S0140-6736(20)32153-X. PMC 7557300. PMID 33069277.
- Meyerowitz-Katz G, Merone L (December 2020). "A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates". International Journal of Infectious Diseases. 101: 138–148. doi:10.1016/j.ijid.2020.09.1464. PMC 7524446. PMID 33007452.
- Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. (February 2021). "Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis". The Lancet. Infectious Diseases. 21 (2): 203–212. doi:10.1016/S1473-3099(20)30769-6. PMC 7572090. PMID 33091374.
- Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. (November 2020). "Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study". BMJ. 371: m4509. doi:10.1136/bmj.m4509. PMC 7690290. PMID 33246972.
- O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DA, Azman AS, Paireau J, et al. (February 2021). "Age-specific mortality and immunity patterns of SARS-CoV-2". Nature. 590 (7844): 140–145. Bibcode:2021Natur.590..140O. doi:10.1038/s41586-020-2918-0. PMID 33137809. S2CID 226244375.
- Hauser A, Counotte MJ, Margossian CC, Konstantinoudis G, Low N, Althaus CL, Riou J (July 2020). "Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe". PLOS Medicine. 17 (7): e1003189. doi:10.1371/journal.pmed.1003189. PMC 7386608. PMID 32722715.
- Lazzerini M, Putoto G (May 2020). "COVID-19 in Italy: momentous decisions and many uncertainties". The Lancet. Global Health. 8 (5): e641–e642. doi:10.1016/S2214-109X(20)30110-8. PMC 7104294. PMID 32199072.
- "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 22 February 2021. Archived from the original on 4 March 2021. Retrieved 4 March 2021.
- Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi:10.1371/journal.pone.0234765. PMC 7310678. PMID 32574165. S2CID 220046286.
- "Coronavirus Disease 2019 (COVID-19) – Symptoms". Centers for Disease Control and Prevention. 22 February 2021. Retrieved 19 January 2022.
- Paderno A, Mattavelli D, Rampinelli V, Grammatica A, Raffetti E, Tomasoni M, et al. (December 2020). "Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects". Otolaryngology–Head and Neck Surgery. 163 (6): 1144–1149. doi:10.1177/0194599820939538. PMC 7331108. PMID 32600175.
- Chabot AB, Huntwork MP (September 2021). "Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia". Cureus. 13 (9): e17829. doi:10.7759/cureus.17829. PMC 8502749. PMID 34660038.
- Niazkar HR, Zibaee B, Nasimi A, Bahri N (July 2020). "The neurological manifestations of COVID-19: a review article". Neurological Sciences. 41 (7): 1667–1671. doi:10.1007/s10072-020-04486-3. PMC 7262683. PMID 32483687.
- Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, Marr LC (August 2021). "Airborne transmission of respiratory viruses". Science. 373 (6558). Bibcode:2021Sci...373.....W. doi:10.1126/science.abd9149. PMC 8721651. PMID 34446582.
- Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R (May 2021). "Ten scientific reasons in support of airborne transmission of SARS-CoV-2". Lancet. 397 (10285): 1603–1605. doi:10.1016/s0140-6736(21)00869-2. PMC 8049599. PMID 33865497.
- Bourouiba L (July 2021). "Fluid Dynamics of Respiratory Infectious Diseases". Annual Review of Biomedical Engineering. 23 (1): 547–577. doi:10.1146/annurev-bioeng-111820-025044. hdl:1721.1/131115. PMID 34255991. S2CID 235823756.
- Stadnytskyi V, Bax CE, Bax A, Anfinrud P (June 2020). "The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission". Proceedings of the National Academy of Sciences of the United States of America. 117 (22): 11875–11877. doi:10.1073/pnas.2006874117. PMC 7275719. PMID 32404416.
- Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, et al. (March 2021). "Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event". Indoor Air. 31 (2): 314–323. doi:10.1111/ina.12751. PMC 7537089. PMID 32979298.
- Fox D (January 2020). "What you need to know about the novel coronavirus". Nature. doi:10.1038/d41586-020-00209-y. PMID 33483684. S2CID 213064026.
- V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V (March 2021). "Coronavirus biology and replication: implications for SARS-CoV-2". Nature Reviews. Microbiology. 19 (3): 155–170. doi:10.1038/s41579-020-00468-6. PMC 7592455. PMID 33116300.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". The New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945.
- "2019 Novel Coronavirus (2019-nCoV) Situation Summary". U.S. Centers for Disease Control and Prevention (CDC). 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
- "Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans". World Health Organization (WHO). Archived from the original on 15 March 2020. Retrieved 14 March 2020.
- Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. (December 2020). "Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples". Clinical Infectious Diseases. 71 (10): 2663–2666. doi:10.1093/cid/ciaa638. PMC 7314198. PMID 32442256.
- "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
- "Real-Time RT-PCR Panel for Detection 2019-nCoV". U.S. Centers for Disease Control and Prevention (CDC). 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
- Bagheri G, Thiede B, Hejazi B, Schlenczek O, Bodenschatz E (December 2021). "An upper bound on one-to-one exposure to infectious human respiratory particles". Proceedings of the National Academy of Sciences of the United States of America. 118 (49): e2110117118. Bibcode:2021PNAS..11810117B. doi:10.1073/pnas.2110117118. PMC 8670465. PMID 34857639.
- "Viral Load Exposure Factors". ReallyCorrect.com.
- "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2020.
- "Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission". COVID-19 Published Science and Research. U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 30 October 2020.
- Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
- "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment". U.S. Centers for Disease Control and Prevention (CDC). 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
- Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
- Subbarao K (July 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572. PMID 34265245.
- Padilla TB (24 February 2021). "No one is safe unless everyone is safe". BusinessWorld. Retrieved 24 February 2021.
- Vergano D (5 June 2021). "COVID-19 Vaccines Work Way Better Than We Had Ever Expected. Scientists Are Still Figuring Out Why". BuzzFeed News. Retrieved 24 June 2021.
- Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
- Holder J (29 January 2021). "Tracking Coronavirus Vaccinations Around the World". The New York Times. ISSN 0362-4331. Retrieved 23 December 2021.
- The Visual and Data Journalism Team. "Covid vaccines: How fast is progress around the world?". BBC News. Retrieved 18 August 2021.
- Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. (July 2020). "Drug treatments for covid-19: living systematic review and network meta-analysis". BMJ. 370: m2980. doi:10.1136/bmj.m2980. PMC 7390912. PMID 32732190.
- "Coronavirus". WebMD. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
- "EMA CHMP advises use of Pfizer's Covid-19 oral antiviral Paxlovid". www.pharmaceutical-technology.com. 17 December 2021. Archived from the original on 18 December 2021. Retrieved 18 December 2021.
- "Paxlovid LOA 12222021 | FDA". www.fda.gov. Retrieved 23 December 2021.
- Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R (6 April 2021). "Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients". PLOS ONE. 16 (4): e0249788. Bibcode:2021PLoSO..1649788I. doi:10.1371/journal.pone.0249788. PMC 8023501. PMID 33822812. S2CID 233173405.
- Multiple sources:
- Wang Y, Wang Y, Chen Y, Qin Q (June 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. 92 (6): 568–576. doi:10.1002/jmv.25748. PMC 7228347. PMID 32134116.
- Martel J, Ko YF, Young JD, Ojcius DM (May 2020). "Could nasal nitric oxide help to mitigate the severity of COVID-19?". Microbes and Infection. 22 (4–5): 168–171. doi:10.1016/j.micinf.2020.05.002. PMC 7200356. PMID 32387333.
- "Coronavirus recovery: breathing exercises". hopkinsmedicine.org. Johns Hopkins Medicine. Retrieved 30 July 2020.
- Wang L, Wang Y, Ye D, Liu Q (June 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents. 55 (6): 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID 32201353.
- Multiple sources:
- Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi:10.1186/s12916-020-01533-w. PMC 7047369. PMID 32106852.
- Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi:10.1097/CM9.0000000000000744. PMC 7147277. PMID 32044814.
- Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMC 7270177. PMID 32171074.
- Multiple sources:
- "Update to living WHO guideline on drugs for covid-19". BMJ. 371: m4475. November 2020. doi:10.1136/bmj.m4475. PMID 33214213. S2CID 227059995.
- "Q&A: Dexamethasone and COVID-19". World Health Organization. Retrieved 11 July 2020.
- "Home". National COVID-19 Clinical Evidence Taskforce. Retrieved 11 July 2020.
- "COVID-19 Treatment Guidelines". nih.gov. National Institutes of Health. Retrieved 18 January 2021.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (April 2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine. Massachusetts Medical Society. 382 (18): 1708–1720. doi:10.1056/nejmoa2002032. PMC 7092819. PMID 32109013.
- Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. Elsevier BV. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC 7118650. PMID 32178774.
- Kim PS, Read SW, Fauci AS (December 2020). "Therapy for Early COVID-19: A Critical Need". JAMA. American Medical Association (AMA). 324 (21): 2149–2150. doi:10.1001/jama.2020.22813. PMID 33175121. S2CID 226301949.
- "COVID-19 Treatment Guidelines". nih.gov. National Institutes of Health. Retrieved 18 January 2021./
- Hsu J (November 2020). "Covid-19: What now for remdesivir?". BMJ. 371: m4457. doi:10.1136/bmj.m4457. PMID 33214186. S2CID 227060756.
- "Cases, Data, and Surveillance". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 11 February 2021.
- "Infographic: Mutation of SARS-CoV-2 – current variants of concern". European Centre for Disease Prevention and Control. 19 April 2021. Retrieved 3 May 2021.
- "Weekly epidemiological update on COVID-19 – 7 September 2021". 7 September 2021. Retrieved 9 September 2021.
- "A computational biologist weighs in on Omicron, the future of vaccines, and the CDC's variant forecast". STAT. 22 December 2021. Retrieved 22 December 2021.